Zacks Research Issues Optimistic Estimate for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Stock analysts at Zacks Research increased their Q2 2026 EPS estimates for Charles River Laboratories International in a research report issued on Wednesday, March 11th. Zacks Research analyst Team now anticipates that the medical research company will post earnings of $2.85 per share for the quarter, up from their prior estimate of $2.74. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q3 2026 earnings at $2.86 EPS, FY2026 earnings at $10.78 EPS, Q1 2027 earnings at $2.62 EPS, Q2 2027 earnings at $2.65 EPS, Q3 2027 earnings at $3.02 EPS, FY2027 earnings at $11.62 EPS and FY2028 earnings at $12.12 EPS.

A number of other brokerages also recently issued reports on CRL. Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Citigroup increased their target price on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Mizuho decreased their price objective on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research note on Friday, February 20th. Argus set a $200.00 price objective on Charles River Laboratories International in a report on Monday, November 17th. Finally, Robert W. Baird set a $193.00 target price on Charles River Laboratories International in a research report on Thursday, February 19th. Ten investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $203.57.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $168.88 on Thursday. The stock’s 50-day simple moving average is $193.48 and its 200-day simple moving average is $181.14. The firm has a market capitalization of $8.31 billion, a PE ratio of -57.05, a price-to-earnings-growth ratio of 2.86 and a beta of 1.64. Charles River Laboratories International has a fifty-two week low of $91.86 and a fifty-two week high of $228.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. During the same quarter in the prior year, the company posted $2.66 earnings per share. Charles River Laboratories International’s revenue for the quarter was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS.

Hedge Funds Weigh In On Charles River Laboratories International

Institutional investors and hedge funds have recently made changes to their positions in the stock. Tema Etfs LLC purchased a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $26,000. Neo Ivy Capital Management purchased a new stake in Charles River Laboratories International during the second quarter worth about $29,000. Rothschild Investment LLC boosted its holdings in Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after buying an additional 84 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in Charles River Laboratories International during the third quarter worth about $31,000. Finally, Los Angeles Capital Management LLC purchased a new position in Charles River Laboratories International in the fourth quarter valued at about $42,000. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.